Reversibility of Pulmonary Hypertension Following Surgical Atrial Septal Defect Closure in Children with Down Syndrome
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
BACKGROUND: Many Down syndrome (DS) patients have an atrial septal defect (ASD) and associated pulmonary hypertension (PH) from early childhood. ASD closure in DS patients with PH is often controversial due to concerns regarding exacerbation of PH. The aim of this study was to investigate the clinical outcome following surgical ASD closure in children with DS. METHODS: We retrospectively reviewed the medical records of DS patients who underwent surgical ASD patch closure from January 2000 to December 2016. RESULTS: A total of 15 patients underwent surgery for ASD. Prior to ASD patch closure, nine patients were diagnosed with PH, three of whom took medications for PH. The mean age of patients at ASD patch closure was 17.3 months, and the mean diameter of the ASD was 10.2 mm. Three patients who took medications for severe PH underwent ASD patch closure at ages 7, 12, and 25 months. Two patients continued medication for an additional 13 and 21 months, and one patient remained on medication 52 months after ASD closure. PH did not recur following discontinuation of selective pulmonary vasodilators in two patients. Although a moderate degree of PH remained in one patient due to a chronic lung problem, it was improved compared to before ASD closure. No PH was observed in the remaining 12 patients following ASD closure. CONCLUSIONS: A large ASD can be closed even in DS patients with severe PH during early childhood with the support of multiple selective pulmonary vasodilators.
Abstract
BACKGROUND: Many Down syndrome (DS) patients have an atrial septal defect (ASD) and associated pulmonary hypertension (PH) from early childhood. ASD closure in DS patients with PH is often controversial due to concerns regarding exacerbation of PH. The aim of this study was to investigate the clinical outcome following surgical ASD closure in children with DS. METHODS: We retrospectively reviewed the medical records of DS patients who underwent surgical ASD patch closure from January 2000 to December 2016. RESULTS: A total of 15 patients underwent surgery for ASD. Prior to ASD patch closure, nine patients were diagnosed with PH, three of whom took medications for PH. The mean age of patients at ASD patch closure was 17.3 months, and the mean diameter of the ASD was 10.2 mm. Three patients who took medications for severe PH underwent ASD patch closure at ages 7, 12, and 25 months. Two patients continued medication for an additional 13 and 21 months, and one patient remained on medication 52 months after ASD closure. PH did not recur following discontinuation of selective pulmonary vasodilators in two patients. Although a moderate degree of PH remained in one patient due to a chronic lung problem, it was improved compared to before ASD closure. No PH was observed in the remaining 12 patients following ASD closure. CONCLUSIONS: A large ASD can be closed even in DS patients with severe PH during early childhood with the support of multiple selective pulmonary vasodilators.
참고문헌 (24)
- King P, "Management of pulmonary hypertension and Down syndrome", Int J Clin Pract Suppl, 65, pp.8~13 (2011)
- Freeman SB, "Population-based study of congenital heart defects in Down syndrome", Am J Med Genet, 80, pp.213~217 (1998)
- Greenwood RD, "The clinical course of cardiac disease in Down's syndrome", Pediatrics, 58, pp.893~897 (1976)
- Herbert S, "Treatment of pulmonary hypertension in Down's syndrome", J Genet Syndr Gene Ther, 6, pp.273~ (2015)
- Vogel M, "Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects", Heart, 82, pp.30~33 (1999)
- Engelfriet P, "Repaired and open atrial septal defects type II in adulthood : an epidemiological study of a large European cohort", Int J Cardiol, 126, pp.379~385 (2008)
- Balint OH, "Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure", Heart, 94, pp.1189~1193 (2008)
- 김기범, "Pulmonary hypertension in infants with bronchopulmonary dysplasia", Clinical and Experimental Pediatrics, 53(6), pp.688~693 (2010), 대한소아청소년과학회
- Dabestani A, "Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography", Am J Cardiol, 59, pp.662~668 (1987)
- Cua CL, "Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates", Pediatr Cardiol, 28, pp.250~254 (2007)
- Banjar HH, "Pulmonary hypertension(PHT)in patients with Down syndrome : the experience in a tertiary care center in Saudi Arabia", J Pulm Respir Med, 2, pp.115~ (2012)
- Skride A, "Pulmonary arterial hypertension associated with adult congenital heart disease, when inoperable becomes operable : a case report", J Pulm Respir Med, 6, pp.350~ (2016)
- Diaconu CC, "Atrial septal defect in an elderly woman-a case report", J Med Life, 4, pp.91~93 (2011)
- Murphy JG, "Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years", N Engl J Med, 323, pp.1645~1650 (1990)
- Lopes AA, "Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease", Cardiol Young, 19, pp.431~435 (2009)
- Hansmann G, "Pulmonary hypertension in infants, children, and young adults", J Am Coll Cardiol, 69, pp.2551~2569 (2017)
- Myers PO, "Assessment of operability of patients with pulmonary arterial hypertension associated with congenital heart disease", Circ J, 78, pp.4~11 (2014)
- Galiè N, "2015 ESC", ERS guidelines for the diagnosis and treatment of pulmonary hypertension : the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS) : endorsed by : Association for European Paediatric and Congenital Cardiology(AEPC), International Society for Heart and Lung Transplantation(ISHLT), 2016, pp.37, 67~119
- D'Alto M, "Pulmonary arterial hypertension associated with congenital heart disease", Eur Respir Rev, 21, pp.328~337 (2012)
- Dimopoulos K, "Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy", Int J Cardiol, 129, pp.163~171 (2008)
- Galiè N, "Bosentan therapy in patients with Eisenmenger syndrome : a multicenter, double-blind, randomized, placebo-controlled study", Circulation, 114, pp.48~54 (2006)
- Budts W, "Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome", Heart, 86, pp.553~558 (2001)
- Schwerzmann M, "Atrial septal defect closure in a patient with"irreversible"pulmonary hypertensive arteriopathy", Int J Cardiol, 110, pp.104~107 (2006)
- Imanaka K, "Atrial septal defect and severe pulmonary hypertension in an adult who needed nitric oxide inhalation after repair", Kyobu Geka, 51, pp.403~405 (1998)